Literature DB >> 23342235

The case for more intensive use of statins.

Jordan Fulcher1, Anthony Keech.   

Abstract

Year:  2012        PMID： 23342235      PMCID： PMC3539269          DOI： 10.1177/2040622312454045

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN： 2040-6223            Impact factor:   5.091


× No keyword cloud information.
  51 in total

1.  The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.

Authors:  Alawi A Alsheikh-Ali; Marietta S Ambrose; Jeffrey T Kuvin; Richard H Karas
Journal:  Circulation       Date:  2005-05-23       Impact factor: 29.690

2.  Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol.

Authors:  Emil M deGoma; Nicholas J Leeper; Paul A Heidenreich
Journal:  J Am Coll Cardiol       Date:  2008-01-01       Impact factor: 24.094

3.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

4.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Authors:  David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

5.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

Review 6.  Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.

Authors:  Runhua Hou; Anne Carol Goldberg
Journal:  Endocrinol Metab Clin North Am       Date:  2009-03       Impact factor: 4.741

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

8.  Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Authors:  Pierre Amarenco; Larry B Goldstein; Michael Szarek; Henrik Sillesen; Amy E Rudolph; Alfred Callahan; Michael Hennerici; Lisa Simunovic; Justin A Zivin; K Michael A Welch
Journal:  Stroke       Date:  2007-10-25       Impact factor: 7.914

9.  Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study.

Authors:  R B D'Agostino; A J Belanger; W B Kannel; J M Cruickshank
Journal:  BMJ       Date:  1991-08-17

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.